Skip to main content
Sign In

L. Michael Glode, Professor

M.D. Washington University, St. Louis


Department of Medicine
Division of Medical Oncology

Campus Box 8117
RC1-South, L18-8121
Phone: 303-724-3853
Fax:     303-724-3889

Dr. Glode has a long standing interest in GU oncology. He was PI on the study leading to approval of leuprolide and is currently PI on the only national NCI sponsored adjuvant treatment protocol for high risk prostate cancer patients following surgery. His laboratory interests include studies on a toxin-conjugate of GnRH which appears capable of directly killing tumor cells aberrently expressing the GnRH receptor as well as eliminating pituitary gonadotropes. He has additional funded research evaluating the efficacy of a flavanone found in milk thistle, silibinin. This interesting polyphenol has significant anti-tumor activity in animal models and no apparent toxicity. An ongoing study is evaluating the human tolerance (Phase I) and lab studies continue to look at its efficacy as a bladder cancer prevention agent. and enhancer of chemotherapeutic agents.

Lab expertise: Cell cultures, molecular biology techniques, animal models for GU cancers, pre-clinical experimental therapeutics.

Qi L, Robinson WA, Brady BMR, Singh R, and Glodé LM: Relationship between expression of VEGF and its receptors to migration and invasion of human prostate cancer cells in vitro. Anticancer Research 23(5A): 3917-22, 2003.

Tyagi AK, Agarwal C, Singh RP, Shroyer KR, Glodé LM,and Agarwal R: Silibinin down-regulates survivin protein and mRNA expression and causes caspases activation and apoptosis in human bladder transitional-cell papilloma RT4 cells. Biochemical and Biophysical Research Communications 312: 1178-1184, 2003.

Qi L, Nett TM, Allen MC, Sha X, Harrison GS, Frederick BA, Crawford ED, and Glodé LM: Binding and cytotoxicity of conjugated and recombinant fusion proteins targeted to the GnRH receptor. Cancer Research 64: 2090-2095, 2004.

Fung KY, Glodé LM, Green S, and Duncan M: A comprehensive characterization of the peptide and protein constitutents of human seminal fluid. The Prostate 61(2): 171-181, 2004.

Ziada A, Barqawi A, Glode LM, Varella-Garcia M, Crighton F, Majeski S, Rosenblum M, Kane M, Chen L, and Crawford ED: The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate. 60(4): 332-337, 2004.

Tyagi A, Agarwal C, Harrison G, Glodé LM, and Agarwal R: Silibinin causes cell cycle arrest in human bladder transitional cell carcinoma cells by regulating

Latest Publications in PubMed